Industrializing Precision.
10,000 PSI Extraction.

to22s Bio-Systems is engineering the next generation of Supercritical CO₂ Fractionation. We bypass supply chain fragility by upcycling domestic rice-bran into pharmaceutical-grade bioactive constituents.

Hard Asset Strategy

The 69 MPa
Physical Moat.

Standard commercial extractors top out at 35 MPa. We are commissioning a 10,000 PSI (69 MPa) circuit designed to unlock the heavy ferulate esters and triterpene fractions that standard systems leave behind.

By owning the hardware, we move beyond "Work for Charge" bottlenecks. Our vertical integration allows us to produce high-resolution fractions with zero toxic solvent residues, meeting the underserved demand for pharmaceutical-grade botanical standardization.

Equipment Capabilities
Operating Pressure 69 MPa
Feedstock Oryza Sativa
Purity Target >99%
Regulatory Class DSHEA / GRAS

The Biorefinery Model

Upcycling global agricultural waste into precision molecular assets.

Circular Supply

Utilizing domestic rice-milling byproducts as an infinite, low-cost feedstock. We convert a $0.50/kg waste stream into a $1,500/kg clinical asset.

Precision Polish

Integrated Column Chromatography allows for the selective enrichment of bioactive triterpenes, creating the world's most potent natural Bcl-2 modulators.

Domestic Moat

Establishing US-based production to secure feedstock sovereignty and bypass the logistical vulnerabilities of overseas pharmaceutical manufacturing.

Market
Capitalization.

Our two-track model provides immediate cash flow via high-end dietary supplements while funding long-term oncology pipelines.

Target Market Size
$150B
Global Wellness & Oncology

Phase 1: Revenue Generation

Launching a line of "Standardized Oryza Extracts" under DSHEA compliance. Targeted at the aging demographic for prostatic and metabolic support. Low regulatory hurdle, immediate market entry.

Phase 2: Moonshot Expansion

Utilizing supplement profits to fund IND-enabling studies for our 3,12-diol lead asset. Transitioning from wellness to precision oncology licensing deals.

"Owning the infrastructure is the difference between a project and a platform."

Project Readiness

1
IP Portfolio Complete

6 USPTO Provisionals filed covering Lead Assets, Biorefinery Processes, and Multi-Axial Delivery Systems. Structural Moat established.

2
Structural Validation Finalized

V7 Engineering audits and technical specs for the 10,000 PSI circuit finalized. ASTM standards for pressure vessel safety verified.

3
2026 Pilot Operations Launch

Commencement of the 100L pilot run. Initial fractionation yields target 98%+ purity on Oryzanol derivatives.

4
Industrial Scale-Up

Expansion to 5,000L continuous flow extraction. Securing long-term supply agreements with domestic rice-millers.

Ready for the
Industrial Age.

We are currently reviewing SBA financing and strategic partnerships for the 2026 pilot launch. Connect with the technical team for the full prospectus.